Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Rhelion Life Sciences: revenue in quarter ended 30 June 2026 fell 85.38 percent to CAD 0.2 million
Rhelion Life Sciences on 31 August 2026 released results for the quarter ended 30 June 2026. Revenue fell from CAD 1.3 million in the year-ago quarter to CAD 0.2 million, a decline of 85.38 percent. » More on finanzen.net
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 114.8k | 85.85% |
| Gross profit | 46.11k | 83.46% |
| Net profit | -923.75k | 44.05% |
| EBITDA | -826.77k | 39.21% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €7.61m |
Number of shares | 614.12m |
52-week high/low | €0.0392 - €0.00455 |
| Dividends | No |
Beta | 0.96 |
P/E ratio | -2.07 |
PEG ratio | 0.05 |
P/B ratio | 1.07 |
P/S ratio | 3.00 |
Company profile
| Name | RHELION LIFE SCIENCES COR |
| CEO | Todd Michael Shapiro |
| Employees | 104 |